[ad_1]
Cambridge, Massachusetts, June 7, 2021 (Global News Agency) – Solid Biosciences Inc. (NASDAQ:Small database), a life science company focused on advancing meaningful treatments for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the company as chief regulatory officer, effective June 1, 2021.
Dr. Barilero has 30 years of experience as a strategy executive in the healthcare industry, successfully designing innovative and integrated regulatory approaches in the United States, the European Union, Switzerland, China, Japan, and Brazil.
“Dr. Barilero came to us with rich experience in drug development and regulatory science. Her professional knowledge and passion to influence the lives of patients through work perfectly fit our mission to improve the lives of Duchenne patients,” Co-founder and President of Solid Biosciences Said Ilan Ganot, CEO.
Dr. Barilero recently served as a senior advisor to Innouvo, providing strategic regulatory guidance for scientific companies. Prior to her most recent position, she held senior positions in regulatory affairs and pharmacovigilance at Agenus and Poxel in Boston. Prior to this, she served as the vice president of Lundbeck A/S Global Regulatory Science and Policy Director. She played a key role in influencing the external medical and regulatory policy environment. She contributed to the regulatory approvals of Selincro and Tritellix, as well as the approval of Rexulti and Abilify It contributes to the maintenance of central nervous system diseases. Early in her career, she held various leadership positions in pharmacology, clinical science, pharmacovigilance, regulatory affairs, and policy participation in Johnson & Johnson, Roche, Wyeth, and Bristol-Myers Squibb. She started her career as a researcher at the famous European cancer center Gustave Roussy in France.
Dr. Barilero received his PhD in pharmacy and medicinal chemistry from the University of Damascus in Syria, and his Master of Science in Molecular and Cellular Pharmacology, Oncology and Ph.
“With a strong commitment to patients and a drug development approach focused on meaningful results for the Duchenne community, I believe that Solid Biosciences is the same value that drives my life and career,” said Dr. Barilero. “The company’s culture adopts innovative regulatory strategies, and through cross-functional collaboration that integrates scientific principles, clinical value, and patient needs, I believe this will help develop differentiated therapies for neuromuscular diseases, including SGT-001 and SGT-003. I look forward to working with other dedicated members of the management team to realize this vision.”
About Solid Bioscience
Solid Biosciences is a life science company focused on advancing transformative treatments to improve the lives of patients with Duchenne’s disease. We are disease-centered and founded by a family directly affected by Duchenne. Our task is simple and comprehensive-by using our leading gene therapy candidate drug SGT-001 to correct the underlying mutations that cause Duchenne, we strive to solve the core of the disease.For more information, please visit www.solidbio.com.
Investor contact information:
David Carey
Finnish partner
212-867-1768
David.Carey@finnpartners.com
Caitlin Lowe
Solid Bioscience
607-423-3219
Clowie@solidbio.com
Media Contact:
Erich Sandoval
Finnish partner
917-497-2867
Erich.Sandoval@finnpartners.com
[ad_2]
Source link
